http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
임종백,최종락,이창훈 건국대학교 의과학연구소 2004 건국의과학학술지 Vol.13 No.-
Cytomegalovirus (CMV) reactivation in immunocompromised patients such as those undergoing hematopoietic stem cell transplantation (HSCT) and those with HIV infections can cause severe morbidity and mortality despite treatment with appropriate anti-viral agents. The recovery of CMV specific cytotoxic T lymphocytes (CTLs) plays an important role in the reconstitution of CMV specific immunity in immunocompromised patients. Recent studies have reported that CMV reactivation could be successfully treated by adoptive transfer of CMV specific T cell clones from CMV seropositive donors expanded in uitro with CMV infected fibroblasts or lysates of CMV infected cells. Other studies have used immune dominant CMV proteins or peptides to expand CMV-specific cytotoxic T lymphocytes. This review contains clinical manifestation of CMV disease in immunocompromised patients, recent advances of antiviral therapy for CMV disease, the principle of induction of cellular immune response to CMV and clinical application of CMV immunotherapy.
Chung, Hye Won,Kim, Ju Won,Lee, Jong-han,Song, Si Young,Chung, Jae Bock,Kwon, Oh Hun,Lim, Jong-Baeck Lippincott WilliamsWilkins, Inc. 2009 JOURNAL OF CLINICAL GASTROENTEROLOGY Vol.43 No.1
PURPOSE: To identify a desirable serum marker for screening tools for gastric cancer, we evaluated the validity of 3 biomarkers, namely, carcinoembryonic antigen (CEA), pepsinogens (PGs), and high sensitive C-reactive protein (hsCRP). METHODS: We estimated the mean serum levels of CEA, PGs, and hsCRP and compared the sensitivity and specificity of these 3 biomarkers in 378 subjects who were classified into 7 groups: normal, chronic atrophic gastritis, intestinal metaplasia, adenoma, early gastric cancer (EGC), advanced gastric cancer (AGC) without metastasis, and AGC with metastasis (M1). RESULTS: There were no significant differences among the normal, high-risk (chronic atrophic gastritis, intestinal metaplasia, and adenoma), and EGC groups for CEA and hsCRP. However, the levels of CEA were relatively higher in the AGC group with intestinal-type cancer (P<0.01). Likewise, hsCRP was relatively higher in the AGC group with diffuse-type cancer (P<0.01). For the PG I/II ratio, there was no significant difference among the normal, high-risk, and cancer groups, including EGC (P<0.01). In addition, there was a negative correlation with grades (&ggr;s=−0.480, P<0.01). However, the PG I/II ratio was relatively less effective in diffuse-type cancer compared with intestinal-type cancer. The combination of serum hsCRP and the PG I/II ratio had a higher sensitivity (77%) than did the PG I/II ratio alone (61%) in diffuse-type cancers. CONCLUSIONS: The combination of serum hsCRP and PG I/II ratio would be helpful as a screening tool for gastric cancer in high incidence populations and may help to select high-risk subjects in need of further specific invasive screening tools such as endoscopy.
Composite Three-Marker Assay for Early Detection of Kidney Cancer
Su Kim, Dong,Choi, Young Deuk,Moon, Mihyang,Kang, Suki,Lim, Jong-Baeck,Kim, Kyung Min,Park, Kyung Mok,Cho, Nam Hoon American Association for Cancer Research 2013 Cancer epidemiology, biomarkers & prevention Vol.22 No.3
<P><B>Background:</B> Early detection of renal cell carcinoma using serum/plasma biomarkers remains challenging. To validate clinical performance of potential candidate markers for kidney tumors, three-marker assay composed of nicotinamide <I>N</I>-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) was evaluated.</P><P><B>Methods:</B> Patients with kidney cancer and control group were included in the clinical evaluation. Participants were divided into cohorts representing the training group of control group including healthy and benign tumors (<I>n</I> = 102) and patients with kidney cancer (<I>n</I> = 87) that were used to identify criteria for scoring. Then, we developed a three-marker assay that was validated with a cohort of test group samples (<I>n</I> = 100). A scoring method based on the cut-point of each of the three markers was used to evaluate the diagnostic performance of the marker combination.</P><P><B>Results:</B> Plasma levels of NNMT, LCP1, and NM23A were highly elevated in patients with kidney cancer (<I>P</I> < 0.0001). In 289 blind sample tests with control subjects (<I>n</I> = 175) and patients with kidney cancer (<I>n</I> = 114), the diagnostic accuracy of NNMT alone and the three-marker assay was 0.913 and 0.932, respectively. When 90% specificity was defined, the sensitivity of NNMT and the three-marker assay was 71.9% and 95.7%, respectively. The predictive value of the three-marker assay was 87.2% (+PPV) and 97% (−PPV).</P><P><B>Conclusions:</B> The composite assay with NNMT, LCP1, and NM23A was a promising novel serum marker assay for the early detection of malignant kidney tumors covering subtypes of RCC with high diagnostic characteristics.</P><P><B>Impact:</B> NNMT/LCP1/NM23A triple markers could be a helpful screening assay to detect early RCC. <I>Cancer Epidemiol Biomarkers Prev; 22(3); 390–8. ©2013 AACR</I>.</P>
Arbekacin의 methicillin 내성 Staphylococcus aureus와 Pseudomonas aeruginosa에 대한 항균력
정윤섭,이경원,신정원,신희봉,임종백 대한화학요법학회 1997 대한화학요법학회지 Vol.15 No.3
배경 : MRSA와 P. aeruginosao는 흔한 원내 감염균이고 aminoglycoside를 포함한 여러 항균제에 내성인 균주가 많다. Arbekacin은 aminoglycoside제로서 일본에서는 MRSA 감염을 치료를 위해 사용되고 있다. 이 연구에서는 MRSA가 확산되기 시작하던 시기와 근래에 분리된 MRSA에 대한, 그리고 내성양상에 따라서 선택된 P. aeruginosa에 대한 arbekacin의 항균력을 비교하고자 하였다. 방법 : 균주는 세브란스병원에서 분리하였다. P. aeruginosa 균주는 amikacin, ceftazidimie, imipenem 및 ciprofloxacin에 대해 감수성 혹은 내성인 것을 선택하였다. 감수성은 NCCLS 디스크 확산법 및 한천희석법으로 시험하였다. 결과 : Arbekacin≤14㎍/mL는 모든 MRSA 균주를 억제하였다. 1980년과 1996년에 분리한 MRSA에 대한 arbekacin의 MIC_(90)은 2㎍/mL로 같았고, MSSA에 대해서는 0.5 ㎍/mL이었다. MRSA가 높은 내성율을 보인 amicoglycoside부터 나열하면 kanamycin, gentamicin, tobramycin, amikacin, isepamicin의 순이었다. Amikacin 감수성인 P. aeruginosa에 대한 arbekacin의 MIC??은 amikacin 보다 약간 높았으나, ceftazidime, impenem 및 ciprofloxacin에 감수성 혹은 내성인 균주에 대해서 보다는 약간 낮았다. Arbekacin 감수성 균주의 비율은 다른 항균제에 대한 감수성이나 균주의 비율은 다른 항균제에 대한 감수성이나 내성인 균주 군에 따라서 약 1/3 내지 2/3이었다. 결론 : 본 시험관내 감수성 성적으로 볼 때, arbekacin은 MRSA 감염의 치료와, 일부 MRSA와 P. aeruginosa의 혼합감염 치료에 유효할 것으로 사료되었다. Background : Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are very prevalent nosocomial pathogens, often resistant to multiple drugs including various aminoglycosides. Arbekacin is an aminoglycoside used for the treatment of MRSA infections in Japan. The aim of study was to compare the activities of arbekacin against the MRSAs isolated currently and at the start of the spread, and against the selected isolates of P. aeruginosa susceptible or resistant to amikacin, ceftazidime, impenem and ciprofloxacin. Methods : The strains were isolated from Severance Hospital. The NCCLS disk diffusion and agar dilution tests were used and strains inhibited by 4 ㎍/mL of arbekacin was interpreted as susceptible and 16 ㎍/mL resistant. Results : Arbekacm ≤4 ㎍/mL inhibited all of the MRSAs tested. The MiC_(90)s for MRS4s isolated in 1980 and 1996 were equal; 2 ㎍/mL, while that for MSSA was 0.5 ㎍/mL. All of the MRSA were susceptible. The resistance rates. in descending order, were to kanamycin, gentamicin, tobramj-cin, amikacin and isepamicin. MIC,, of arbekacin for amikacin-susceptible P. aerugznosa m-as slightly higher than that of amikacin, but slightly lower than those for the strains both susceptible and resistant to ceftazidxme, imipenem and ciprofloxacin. Depending on the susceptibility groups of strains, approximate15 1/3 to 2/3 were susceptible to arbekacin. Conclusion : Arbekacin may be useful for the treatment of single MRSA infection and for some of the mixed infections of MRSA and P. aerugznosa.